Therapix Biosciences Ltd. (TRPX)
|Net Income (ttm)||n/a|
|Trading Day||Jul 1, 2020|
|Day's Range||0.301 - 0.400|
|52-Week Range||0.250 - 4.690|
TEL AVIV, Israel, July 1, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the develo...
TEL-AVIV, Israel, June 29, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the devel...
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.
Shares of Therapix Biosciences fell 5% in morning trading after the Israeli drugmaker said it would continue to test its experimental cannabinoid-based therapy as an autism treatment.
Cannabis-focused investment company SOL Global Investments Corp. (CSE: SOL) said Tuesday that its portfolio company, Heavenly Rx, Ltd., has entered into a memorandum of understanding with Ther...
Therapix Biosciences, a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Bioscien... [Read more...]
|IPO Date |
Mar 22, 2017
|Stock Exchange |
|Ticker Symbol |